The Urinary Incontinence drugs in development market research report provides comprehensive information on the therapeutics under development for Urinary Incontinence, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Urinary Incontinence. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Urinary Incontinence and features dormant and discontinued products.

GlobalData tracks 21 drugs in development for Urinary Incontinence by 20 companies/universities/institutes. The top development phase for Urinary Incontinence is preclinical with 11 drugs in that stage. The Urinary Incontinence pipeline has 19 drugs in development by companies and two by universities/ institutes. Some of the companies in the Urinary Incontinence pipeline products market are: Profem, Urovant Sciences and Exopharm.

The key targets in the Urinary Incontinence pipeline products market include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25), Sodium Dependent Noradrenaline Transporter (Norepinephrine Transporter or NET or Solute Carrier Family 6 Member 2 or SLC6A2), and Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1).

The key mechanisms of action in the Urinary Incontinence pipeline product include Synaptosomal Associated Protein 25 (Synaptosomal Associated 25 kDa Protein or Super Protein or SNAP25) Inhibitor with two drugs in Phase 0. The Urinary Incontinence pipeline products include 12 routes of administration with the top ROA being Intramuscular and four key molecule types in the Urinary Incontinence pipeline products market including Cell Therapy, and Small Molecule.

Urinary Incontinence overview

Urinary incontinence is a loss of control of the bladder. In some cases, it may result in a total loss of the bladder’s contents or it may just cause minor leakage. Symptoms include stress incontinence, rashes, and other skin disorders. Risk factors include age, gender, overweight, smoking, and kidney diseases. Treatment includes anticholinergics and topical estrogen.

For a complete picture of Urinary Incontinence’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.